What is the ticker symbol for Aravive?

Aravive trades under the ticker ARAV on NASDAQ.

What sector does Aravive operate in?

Aravive is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze ARAV in a portfolio?

PortView shows ARAV's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

Aravive (ARAV) Stock Analysis

NASDAQHealthcareBiotechnology

$0.04-13.39%

1-year price historyRange $0.04 – $2.46

52-week range$0.04

$0.04$2.46

What Aravive does

Aravive, Inc. is a clinical-stage biopharmaceutical company, based in Houston, Texas, dedicated to discovering and developing innovative treatments for life-threatening illnesses such as cancer and fibrosis. The company's primary therapeutic candidate, batiraxcept, is an ultrahigh-affinity decoy protein engineered to disrupt the GAS6-AXL signaling pathway. This drug is currently progressing through a Phase III clinical trial for platinum-resistant recurrent ovarian cancer, and is also being evaluated in Phase Ib/II studies for clear cell renal cell carcinoma and pancreatic adenocarcinoma. Aravive also has AVB-S6 in its pipeline, a soluble Fc-fusion protein aimed at blocking the activation of the same GAS6-AXL pathway. Beyond internal development, Aravive has forged strategic partnerships. This includes a collaboration with WuXi Biologics (Hong Kong) Limited to develop novel, high-affinity bispecific antibodies targeting cancer and fibrosis. Furthermore, a license agreement with 3D Medicines Inc. grants rights to develop and commercialize products featuring batiraxcept as the sole active ingredient for human oncological diseases across mainland China, Taiwan, Hong Kong, and Macau. Originally incorporated in 2008 as Versartis, Inc., the company adopted the name Aravive, Inc. in October 2018.

Key metrics

Market cap

$2.95M

P/E (TTM)

-0.05

EPS (TTM)

$-0.76

Beta

2.19

Dividend yield

0.00%

Revenue / share

$0.25

50-day avg

$0.10

200-day avg

$0.59

52-week high

$2.46

52-week low

$0.04

CEO

Fredric N. Eshelman

ETFs linked to ARAV

Broad-market and Healthcare sector ETFs an investor holding Aravive is often also exposed to. Open an ETF page to see its actual top holdings.

SPY — SPDR S&P 500 ETF Trust VOO — Vanguard S&P 500 ETF QQQ — Invesco QQQ Trust VTI — Vanguard Total Stock Market ETF

PortView Portfolio Insights

PortView analyzes how ARAV fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze ARAV in PortView →

Similar companies

JNJ — Johnson &LLY — Eli Lilly A — Agilent Technologies ABBV — AbbVie Inc.ABT — Abbott Laboratories ALNY — Alnylam Pharmaceuticals

Frequently asked questions

What is the ticker symbol for Aravive?: Aravive trades under the ticker ARAV on NASDAQ.
Which exchange is ARAV listed on?: ARAV is listed on NASDAQ.
What sector does Aravive operate in?: Aravive is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze ARAV in a portfolio?: PortView shows ARAV's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.